On June 22, 2026, China’s National Medical Products Administration (NMPA) officially approved Silevimig Injection (Jinsuxi®), independently developed by Genrix Biopharmaceutical, for rabies passive immunization in adults following exposure to Rabies Virus (RABV). The approval of…
On June 22, 2026, China’s National Medical Products Administration (NMPA) approved Satricabtagene Autoleucel (Kailimei®), developed by CARsgen Therapeutics, for the treatment of patients with CLDN18.2-positive, HER2-negative advanced gastric cancer or gastroesophageal junction (GEJ) adenocarcinoma who…
On June 22, 2026, NMPA officially approved Biokin Pharmaceutical’s independently developed Class 1 innovative drug, Izalontamab Brengitecan (brand name: Yizekang), for marketing in China. It is indicated for adult patients with recurrent or metastatic nasopharyngeal…
On June 11, China’s National Medical Products Administration (NMPA) officially approved Wuhan Createrna Science and Technology’s self-developed lanoracopan hydrochloride tablets (Yishining®) for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have not…
On June 11, Akeso announced that its self-developed IL-17A monoclonal antibody, Gumokimab (AK111, brand name Qiyoukang®), received approval from China’s National Medical Products Administration (NMPA) for the treatment of adults with moderate-to-severe plaque psoriasis. The…
On June 4, 2026, the NMPA officially announced that injectable Bemiltenase alfa (STSP-0601), a Class 1 innovative biologic developed by BioJeTay, a subsidiary of Shutaishen Pharmaceutical Group, received conditional approval in China. The drug is…
China’s innovative drug industry continues to achieve major breakthroughs. According to public information released by China’s National Medical Products Administration (NMPA), May 2026 China innovative drug approvals included 5 newly approved therapies covering insomnia, myasthenia…
On May 21, Johnson & Johnson announced that its FcRn antagonist Imaavy® (nipocalimab injection) received approval from China’s National Medical Products Administration (NMPA) for use in combination with standard therapy in adolescents aged 12 years…
On May 15, 2026, AbbVie announced that its CD20×CD3 bispecific antibody — Epkinly (Epcoritamab) — has been approved by China’s National Medical Products Administration (NMPA). This marks a significant milestone in lymphoma treatment, as epcoritamab…
April 2026 marked another milestone for China innovative drug approvals April 2026, as the country witnessed a new wave of regulatory clearances across oncology, hematology, nuclear medicine, and inflammatory diseases. According to public information released…
On April 27, 2026, the National Medical Products Administration (NMPA) announced that Jiangsu Huayang Pharmaceutical’s extended-release tablets became the first generic upadacitinib approved in China after passing generic consistency evaluation. This milestone—generic upadacitinib approved in…
On April 17, China’s National Medical Products Administration (NMPA) approved belantamab mafodotin in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least…
